Recursion Pharmaceuticals, Inc. upgraded to Buy on promising REC-4881 data, strong partnerships, and AI-driven drug discovery ...
Abstract: Robot navigation in an unknown environment is a challenging task, due to the lack of spatial awareness and semantic understanding of the environment. Previous works predominantly relied on ...
Abstract: The climatic sensitivity of new terrain-aware backtracking algorithms is evaluated across 800 locations in the continental USA on a representative synthetic rolling terrain. We find that a ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback